WO2019065674A1 - Agent améliorant l'arthrose - Google Patents

Agent améliorant l'arthrose Download PDF

Info

Publication number
WO2019065674A1
WO2019065674A1 PCT/JP2018/035563 JP2018035563W WO2019065674A1 WO 2019065674 A1 WO2019065674 A1 WO 2019065674A1 JP 2018035563 W JP2018035563 W JP 2018035563W WO 2019065674 A1 WO2019065674 A1 WO 2019065674A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
integer
salt
trans
Prior art date
Application number
PCT/JP2018/035563
Other languages
English (en)
Japanese (ja)
Inventor
横山　富久
康宏 西田
Original Assignee
アスタファーマシューティカルズ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスタファーマシューティカルズ株式会社 filed Critical アスタファーマシューティカルズ株式会社
Publication of WO2019065674A1 publication Critical patent/WO2019065674A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to an agent for improving osteoarthritis comprising an astaxanthin derivative.
  • Astaxanthin is widely known to have potentially strong anti-inflammatory effects.
  • omega-3 fatty acid-containing lipids, neutral fats, antioxidants such as ⁇ -tocopherol, pigments such as astaxanthin, extraction of krills containing metals such as zinc and / or marine organisms A high concentration capsule of the substance oil is orally administered to a group of patients with osteoarthritis, and in many of them there is a remarkable alleviation effect of pain and a remarkable improvement effect of the flexibility of large joints (lower spine, knees, shoulders) Have been reported (see Example 2 of each document).
  • the main object of the present invention is to provide an osteoarthritis improving agent having a further improving effect on osteoarthritis.
  • the present inventors diligently studied to find new therapeutic agents as a remedy for osteoarthritis, and as a result, the trans-astaxanthin derivative represented by the formula (I), its geometric isomer, a mixture of these geometric isomers, The inventors have found that their optical isomers or their salts have excellent therapeutic effects on osteoarthritis and completed the present invention.
  • the present invention provides the following inventions [1] to [4].
  • n 1 , n 2 are the same or different and each represents an integer of 1 to 6).
  • trans-astaxanthin derivative represented by the above formula (I), its geometric isomer, a mixture of these geometric isomers, their optical isomers or a salt thereof for producing an osteoarthritis improving agent .
  • a deformability characterized by administering an effective amount of the trans-astaxanthin derivative represented by the above formula (I), its geometric isomer, a mixture of these geometric isomers, their optical isomers or their salts Methods of treating arthropathy.
  • trans-astaxanthin derivative represented by the formula (I) of the present invention is various animals such as humans, dogs, cats and horses in general.
  • astaxanthin derivative of the formula (I) its geometric isomer, a mixture of these geometric isomers, an optical isomer thereof or a salt thereof
  • These pharmaceutical compositions are excellent as osteoarthritis improving agents.
  • the osteoarthritis improving agent of the present invention comprises, as an active ingredient, the trans-astaxanthin derivative represented by the above formula (I), its geometric isomer, a mixture of these geometric isomers, their optical isomers or their salts contains.
  • “Deroarthritis” is a joint disease mainly involving chronic arthritis that develops in joints such as wrists, elbows, shoulders, necks, hips, hips, knees, ankles, and toes, etc. It is a disease that causes destruction of cartilage and proliferative changes of bone and cartilage due to progressive degeneration.
  • the improvement of osteoarthritis related to the present invention can be expected to have a remarkable effect especially in osteoarthritis of the knee.
  • “Amelioration” of osteoarthritis is meant to include not only the improvement of the symptoms of osteoarthritis itself but also the alleviation or analgesia of pain caused by osteoarthritis.
  • the compound according to formula (I), its geometric isomer, a mixture of these geometric isomers and optical isomers thereof have a common salt-forming reaction with a basic substance or a basic compound desired from having a carboxyl group in the molecule
  • a pharmaceutically acceptable salt can be formed by Such salts include, for example, alkali metal salts such as sodium salts, potassium salts and lithium salts; alkaline earth metal salts such as calcium salts and magnesium salts, amino acids such as lysine salts, ornithine salts and arginine salts Salt can be mentioned.
  • the double bond part in the medium chain carbon chain part in the astaxanthin basic skeleton can take on the structure of trans and cis geometric isomers in terms of chemical structure.
  • the active ingredient according to the present invention not only the trans form of formula (I) but also cis forms represented by the following formula (Ia) and formula (Ib) are effective in the osteoarthritis improving agent according to the present invention It can be mentioned as an ingredient.
  • the osteoarthritis improving agent of the present invention also includes, as an active ingredient, a mixture of trans form of formula (I) and cis form which is its geometric isomer in various mixing ratios.
  • the compound of the formula (I), its geometric isomer and a mixture of these geometric isomers may include the optical isomer (IA) represented by the following, and its enantiomer and a mixture thereof, All diastereomers are also included as active ingredients of the osteoarthritis improving agent according to the present invention.
  • the compounds of the trans form of the above-mentioned formula (IA) are preferred. Further, among the trans compounds of the above formula (IA), compounds in which m 1 and m 2 each represent an integer of 1 and n 1 and n 2 each represent an integer of 3 are preferable.
  • an optically active trans-astaxanthin derivative represented by the formula (IA) or a salt thereof is more preferable, and an optically active cis-astaxanthin derivative corresponding to the optically active trans-astaxanthin derivative represented by the formula (IA) More preferred is a highly pure optically active trans-astaxanthin derivative substantially free of a salt or a salt thereof.
  • containing the active ingredient of the osteoarthritis improving agent according to the present invention in "high purity" means that the purity in the active ingredient is at least 95% or more, preferably 98% or more.
  • the target optically active trans-astaxanthin derivative of the formula (IA) can be produced by removing the protecting group of the compound of the formula (II) which is a starting compound.
  • the elimination reaction may be a conventional elimination reaction of a protecting group, and specifically, an elimination reaction with an acid can be mentioned.
  • a protecting group a tertiary butyl group, a trimethylsilyl group, a tetrahydropyranyl group etc. can be mentioned, A tertiary butyl group, a trimethylsilyl group etc. can be mentioned as a suitable thing.
  • the compound of formula (IA) can be produced by reacting the compound of formula (II) with an acid in an inert solvent.
  • the solvent used is not particularly limited as long as it is inert to the reaction, and examples thereof include aliphatic hydrocarbons such as hexane, heptane, ligroin and petroleum ether; aromatics such as benzene, toluene and xylene Hydrocarbons; Halogenated hydrocarbons such as chloroform, methylene chloride, 1,2-dichloroethane and carbon tetrachloride; Nitriles such as acetonitrile and propionitrile; ethyl formate, isopropyl formate, isobutyl formate, ethyl acetate, Organic acid esters such as isobutyl acetate and butyl acetate; ethers such as diethyl ether, diisopropyl ether, tetrahydro
  • the acid which can be used is not particularly limited as long as it is used as an acid in a usual reaction, and, for example, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, perchloric acid and phosphoric acid; acetic acid, formic acid Organic acids such as boric acid, methanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid; zinc chloride, tin tetrachloride, boron trichloride, boron trifluoride, boron tribromide Or a acidic ion exchange resin, preferably an inorganic or organic acid, most preferably hydrochloric acid, acetic acid, formic acid and trifluoroacetic acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, perchloric acid and phosphoric acid
  • acetic acid
  • the reaction temperature varies depending on the raw material compound to be reacted, the acid used, the solvent and the like, but is usually ⁇ 20 ° C. to 150 ° C., preferably 0 ° C. to 100 ° C.
  • the reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 30 minutes to 10 days, and preferably 30 minutes to 5 days.
  • the amount of the solvent used may be 10 to 50 times, preferably 30 times the volume of the weight of the compound of formula (II).
  • the amount of the acid used is usually 5 to 50 times by mole, preferably 10 to 30 times by mole, as long as it is an inorganic acid relative to the compound of the formula (II) which is the raw material, an organic acid
  • the molar amount is usually 100 to 1000 times, preferably 200 to 600 times.
  • the product obtained by the above deprotection reaction can contain geometric isomers such as the above 9-cis form and 13-cis form, so that separation and purification means such as column chromatography, reprecipitation and crystallization can be obtained.
  • separation and purification means such as column chromatography, reprecipitation and crystallization.
  • the same geometric isomer can be separated and removed, and the objective optically active trans-astaxanthin derivative of the formula (IA) can be isolated and manufactured with high purity.
  • the separated cis-form can be isolated and obtained by appropriately combining the purification and separation methods as described above.
  • Representative cis-forms used in this production method are the compounds of the formulas (IAa) and (IAb) as described above, which may be used as sole raw material compounds, as a mixture of cis-forms, or in excess of cis-forms.
  • the desired optically active trans-astaxanthin derivative of the formula (IA) can be produced by dissolving it in an inert solvent as a mixture with the trans form and reacting it with a conversion reagent such as iodine. .
  • the solvent to be used is not particularly limited as long as it is inert to the reaction, and examples thereof include tetrahydrofuran, ethyl acetate, acetonitrile, acetone, water and the like.
  • Preferred examples of the conversion reagent include iodine.
  • the reaction temperature varies depending on the raw material compound to be reacted, the conversion reagent to be used, the solvent and the like, but is usually ⁇ 20 ° C. to 150 ° C., preferably 10 ° C. to 100 ° C.
  • the reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 30 minutes to 10 days, and preferably 30 minutes to 5 days.
  • the amount of the solvent used may be 10 to 50 times the used weight of the compound of formula (IAa) or (IAb), and preferably 30 times the volume.
  • the amount of conversion reagent used may be usually 0.01 times or more by mole, preferably 0.1 times or more by mole, of the compound of the formula (IAa) or formula (IAb) as a raw material.
  • (2A) A method for directly binding the entire side chain moiety to 3S, 3'S-astaxanthin
  • R means a protecting group (eg, tertiary butyl group).
  • a compound of formula (II) is obtained by dissolving 3S, 3'S-astaxanthin in an inert solvent and then reacting the compound of formula (III) corresponding to the side chain moiety in the compound of formula (I) in the presence of a condensing reagent. Can be manufactured.
  • the solvent examples include organic solvents such as methylene chloride, chloroform and carbon tetrachloride.
  • the condensation reagent those used in ordinary condensation reactions can be used, and as a specific example, water-soluble carbodiimide hydrochloride (eg, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride) And N, N-diisopropylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide and the like.
  • the amount of the condensation reagent used is usually at least 2 times the molar amount, preferably 2.5 times to 20 times the molar amount of the raw material 3S, 3'S-astaxanthin.
  • the compound of the formula (III) corresponding to the side chain moiety may be used usually in a 2-fold molar amount or more, preferably 2.5-fold molar to 20-fold molar amount with respect to 3S, 3'S-astaxanthin.
  • the reaction temperature varies depending on the raw material compound to be reacted, the condensation reagent to be used, the solvent and the like, but is usually ⁇ 20 ° C. to 150 ° C., preferably ⁇ 10 ° C. to 100 ° C.
  • the reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 30 minutes to 10 days, and preferably 30 minutes to 5 days.
  • the amount of the solvent used is usually 10 to 50 times the used weight of 3S, 3'S-astaxanthin, preferably 30 times the volume.
  • the compound of the formula (II) obtained can be usually purified and isolated by appropriately combining purification means such as column chromatography, reprecipitation, recrystallization and the like.
  • the whole side chain part can be manufactured by the following method.
  • R means a protecting group (eg, tertiary butyl group).
  • the desired compound of formula (III) can be produced by sequentially reacting the compound of formula (IV) with the compound of carbonyldiimidazole (V) and the compound of formula (VII).
  • the compound of formula (IV) is an intermediate compound of formula (VI) by reacting carbonyldiimidazole (V) in the presence or absence of a reagent such as a base in an inert solvent.
  • a reagent such as a base in an inert solvent.
  • the desired compound of formula (III) can be produced by reacting the compound of formula (VII) with trimethylsilyl chloride in the presence of a reagent such as a base and then reacting with the compound of formula (VI) .
  • organic solvents such as chloroform and methylene chloride can be exemplified as the solvent, and the amount of these organic solvents used is usually 5 times the used weight of the compound of the formula (IV)
  • a volume of 30 to 30 volumes, preferably 15 volumes, may be used.
  • the basic reagent those used for ordinary condensation reactions can be used, and specific examples can include triethylamine, N, N-diisopropylethylamine, pyridine, N, N-dimethylaminopyridine and the like.
  • the reaction temperature varies depending on the raw material compound to be reacted, the reagent used, the solvent and the like, but is usually ⁇ 20 ° C.
  • reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 15 minutes to 10 days, and preferably 30 minutes to 2 days can be mentioned.
  • organic solvents such as chloroform, methylene chloride, pyridine and the like can be mentioned as solvents for reacting trimethylsilyl chloride and the compound of formula (VII).
  • the amount used is usually 5 times to 50 times the volume, preferably 20 times the volume of the used weight of the compound of the formula (VII).
  • the base those used for ordinary condensation reactions can be used, and specific examples can include triethylamine, N, N-diisopropylethylamine, pyridine, N, N-dimethylaminopyridine and the like.
  • the amount of the base or reagent used is usually at least 2 moles, preferably 2.5 to 5.0 moles, per mole of the compound of the formula (VI) as the raw material.
  • the reaction temperature varies depending on the raw material compound to be reacted, the reagent used, the solvent and the like, but is usually ⁇ 20 ° C. to 100 ° C., and preferably 0 ° C. to 30 ° C.
  • the reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 15 minutes to 5 days, and preferably 30 minutes to 2 days can be mentioned.
  • the compound of formula (VI) is added and reacted at a reaction temperature which varies depending on the starting compound to be reacted, the reagent to be used, the solvent and the like, but is usually -20 ° C to 150 ° C, preferably 10 ° C. To 60 ° C.
  • the reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 30 minutes to 10 days, and preferably 30 minutes to 4 days.
  • R means a protecting group (eg, tertiary butyl group or trimethylsilyl group).)
  • the side chain part (VIII) obtained by reacting the compound represented by the general formula (VII) with carbonyldiimidazole (V) is bound to 3S, 3'S-astaxanthin, This can then be achieved by coupling part (XI) of the side chain part to the obtained product (IX).
  • reaction temperature varies depending on the raw material compound to be reacted, the reagent to be used, the solvent and the like, but is usually ⁇ 20 ° C. to 150 ° C., preferably ⁇ 10 ° C. to 100 ° C.
  • the reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 30 minutes to 10 days, and preferably 30 minutes to 5 days.
  • bases include triethylamine, N, N-diisopropylethylamine, pyridine, N, N-dimethylaminopyridine and the like.
  • the compound of the formula (IX) can be produced by reacting the resulting part of the side chain part (VIII) with 3S, 3'S-astaxanthin in the same manner as in the reaction of 2A above. .
  • the step of obtaining the target general formula (II) can be achieved by reacting the compound having the general formula (IX) obtained above with the general formula (XI).
  • This reaction is carried out according to the method for producing the above general formula (VIII).
  • the reaction temperature varies depending on the raw material compound to be reacted, the reagent to be used, the solvent and the like, but is usually ⁇ 20 ° C. to 100 ° C., preferably 0 ° C. to 40 ° C.
  • the reaction time varies depending on the raw material compound, the solvent, the reaction temperature and the like, but is usually 30 minutes to 10 days, and preferably 30 minutes to 30 hours.
  • the method for producing a compound having the general formula (XI) can be achieved according to the method for synthesizing t-butyl ester of generally known amino acid when (1) R is a t-butyl group, (2) When R is a trimethylsilyl group, it can be achieved by reacting a compound having the general formula (X) with trimethylsilyl chloride in the presence of a base in an inert solvent (to form a compound of the general formula (III) It can be achieved according to the method).
  • the reaction of (2) can be achieved according to generally known methods for silylation of hydroxyl and carboxyl groups.
  • R in the general formula (XI) is a trimethylsilyl group
  • the trimethylsilyl group can be easily eliminated by using water or weakly acidic water for post-treatment of the reaction to generate the general formula (II). .
  • the desired compound of the formula (II) can be produced by using the obtained product in combination with purification methods such as ordinary column chromatography, reprecipitation, recrystallization and the like as appropriate.
  • the compounds of the formula (I), their geometric isomers, mixtures of these geometric isomers, their optical isomers, as described in the examples below, improve the symptoms of osteoarthritis, in particular alleviating pain or excellent pain It has an analgesic effect.
  • osteoarthritis develops in various joints such as the wrist, elbow, shoulder, neck, waist, hips, hips, knees, ankles, fingers and toes, and is effective for any osteoarthritis in the present invention.
  • it is more effective for osteoarthritis of the knee, osteoarthritis of the hip, and osteoarthritis, especially for osteoarthritis of the knee and osteoarthritis, especially osteoarthritis of the knee.
  • symptoms of osteoarthritis include pain, swelling, deformation of joints, muscle weakness and the like, and in the present invention, it is effective for the alleviation of all the symptoms, and is particularly excellent in the pain improvement effect.
  • the compounds of the formula (I) according to the present invention are generally used in medical fields and foods, such as injections, oral agents, in vivo placement, etc. Any method used in the field can be administered without particular limitation.
  • the administration time may be before eating, after eating, between meals, before going to bed, or a combination of these.
  • the number of daily doses is also not particularly limited.
  • the injection can be produced by a usual formulation technique, using an appropriate combination of a pharmaceutically acceptable osmotic pressure regulator, a stabilizer, a solubilizer, a pH regulator and the like.
  • the oral preparation may be administered in any form such as tablets, capsules, granules, powders and the like, and is appropriately mixed with pharmaceutically acceptable excipients, disintegrants, binders and other pharmaceutical additives, It can be produced by using conventional formulation techniques.
  • the compound of the formula (I) according to the present invention, its geometric isomer, a mixture of these geometric isomers, their optical isomers or a salt thereof may be administered as an injection, as in existing pharmaceuticals, It may be administered as an agent, may be administered as an external preparation such as a patch, an ointment and the like, and may be administered in a topical administration form.
  • the compound of the formula (I) according to the present invention may be mixed with other drugs or pharmaceutical additives and co-administered.
  • the drug used in combination is not particularly limited, and drugs that can be used generally as pharmaceuticals, such as hyaluronic acid, digestive aids, intestinal stabilizers, antiulcer agents, antibiotics, hormones, enzymes, steroids, endocrine drugs, cardiovascular agents, anti drugs Rheumatic agents, anti-inflammatory agents, analgesics, antipyretics, anti-allergic agents, antitumor agents, and further, peptides such as interferons, interleukins, tumor necrosis factors and the like may be used.
  • the pharmaceutical additive is also not particularly limited, and any one that can be used as a pharmaceutical can be used.
  • a compound of the formula (I) according to the present invention When a compound of the formula (I) according to the present invention, a geometric isomer thereof, a mixture of these geometric isomers, an optical isomer thereof or a salt thereof is administered as an injection, it is usually per day for adults And 5.0 mg to 50 mg may be administered into the joint cavity, and may be increased or decreased appropriately according to the symptoms.
  • the compounds of the formula (I) according to the present invention, their geometric isomers, mixtures of these geometric isomers, their optical isomers or salts thereof are particularly problematic in terms of safety within the above-mentioned dose range. Absent.
  • analgesic test was conducted using a rat model in which osteoarthritis (OA) was induced using monoiodoacetic acid sodium salt (MIA).
  • OA osteoarthritis
  • MIA monoiodoacetic acid sodium salt
  • Model Preparation Crl CD (SD) rats were prepared, and Japanese Pharmacopoeia isoflurane (manufactured by Mylan Pharmaceutical Co., Ltd.) was prepared as an inhalation anesthetic.
  • Osteoarthritis (OA) was administered 50 ⁇ L (2 mg / site) of monoiodoacetic acid sodium salt (MIA, manufactured by Sigma-Aldrich) into the right knee joint cavity of a rat under 2% inhalation anesthesia with inhalation anesthetic. Induced.
  • MIA monoiodoacetic acid sodium salt
  • the resulting organic layer solution was washed with a mixture of hydrochloric acid (5.66 kg) and 20% brine (106 kg).
  • the aqueous layer was mixed with ethyl acetate (57.4 kg), extracted with ethyl acetate, and the organic layer and the extract were combined.
  • the resulting solution was washed with 20% brine (100 kg), dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
  • Ethyl acetate (14.4 kg) was added and stirred to a homogeneous solution at 45-55 ° C.
  • the solution was cooled to 20-30 ° C., n-heptane (108.7 kg) was added dropwise, and after confirming the precipitation of crystals, the solution was stirred for 1 hour.
  • the precipitated crystals were collected by filtration to give the title compound (7.98 kg, purity 99.2%) as white crystals.
  • the obtained solution was treated three times with hydrochloric acid (0.3 M, 46.4 kg), 10% saline (45.9 kg), aqueous sodium hydrogen carbonate solution (about 7%, 48.2 kg), 20% saline (45 kg)
  • the extract was successively washed with water, dried over anhydrous magnesium sulfate, and concentrated to dryness under reduced pressure to obtain the title compound (concentrated residue, 3.26 kg, purity 98.1%).
  • the purity of the product is determined by high performance liquid chromatography (column: YMC-TriartC18 ExRS manufactured by YMC Co., Ltd.
  • the precipitated solid was collected by filtration and dried to give the title compound (4.48 g, purity 90.7%) as a dark purple to dark red solid.
  • acetonitrile containing 0.025% trifluoroacetic acid / 0.025% trifluoroacetic acid water 30 to 98 / It was determined using 70-2, flow rate: 1 mL / min, detection wavelength: 474 nm).
  • the optical purity is high performance liquid chromatography (column: YMC, YMC CHIRAL ART Amylase SA (5 ⁇ m, 4.6 mm ID x 250 mm), column temperature: 25 ° C and mobile phase: THF / water / TFA (40:60) : 0.1), flow rate: 1 mL / min, detection wavelength: 474 nm, column retention time: 15.4 minutes (S, S), 17.6 minutes (meso), 20.6 minutes (R, R)) Used to determine.
  • Pain measurement 1 (4.1) Weight measurement of left and right hind limbs Weight of left and right hind paws of test animals, once a week (administered twice weekly for the test substance: 3 days after the first administration for the second administration), 7 days After 14 days, 21 days, 28 days, it measured over 4 weeks.
  • Incapacitance Tester manufactured by Linton Instrument
  • the animals were placed in a dedicated folder, and the left and right hind limbs were placed on weight meters equipped at two places, respectively, to perform measurement. And the ratio (weight load ratio) of the weight of the left foot and the weight of the right foot was calculated to evaluate the degree of pain.
  • the weight-bearing ratio was 0.60, 0.61, 0.58 and 0.61 before administration, 7 days, 14 days, 21 days and 28 days after administration of the control group.
  • the weight-loading ratio of Compound X administration group before, 7, 14, 21, 21 and 28 days after administration was 0.60, 0.62, 0.60, 0.60 at a compound X concentration of 0.01 mg / knee.
  • the compound X concentration is 0.60, 0.63, 0.61, 0.63, and 0.64 at 0.1 mg / knee, and the compound X concentration is 0.60 at 1 mg / knee. , 0.61, 0.63, 0.65 and 0.66.
  • Pain measurement 2 (5.1) Measurement of pain threshold (mechanical stimulation) The pain threshold (g) of the right footpad was measured once per animal on the same day as the weight measurement day of the left and right hind limbs.
  • a Dynamic Plantar Aesthesiometer (Cat. No. 37400, manufactured by Ugo Basile) was used as a measurement device. The mechanical stimulation conditions were set to 30.0 g maximum pressure and 40 seconds to reach the maximum pressure.
  • Statistical analysis performed Student's t-test for every measurement time point. In both cases, a risk ratio of less than 5% (P ⁇ 0.05) was determined to be significant on both sides. All results are shown as mean ⁇ standard error.
  • EXSUS Version 7.7.1 CAC Corporation, Inc.
  • SAS 9.1.3 SAS Institute Japan Co., Ltd.
  • the pain thresholds of the control group were 11.3, 10.4, 10.2, 10.0 and 9.9 g before, 7, 14, 21 and 28 days after administration.
  • the pain threshold values before administration, 7, 14, 21, 21 and 28 days of the compound X administration group are 11.3, 10.9, 11.0, 10.6 and 0.01 at a compound X concentration of 0.01 mg / knee. It is 10.5 g, the compound X concentration is 11.3, 11.0, 11.4, 11.8 and 12.1 in the 0.1 mg / knee group, and the compound X concentration is 11.4 in the 1 mg / knee. , 10.5, 11.1, 13.3 and 13.4.
  • each measured value of a pain threshold value has shown the average value +/- standard error of ten rats.
  • "*" is P value ⁇ 0.05 (P value between control group and compound X administration group is less than 5%)
  • "**” is P value It means that it is ⁇ 0.01 (P value between the control group and the compound X administration group is less than 1%), respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un nouvel agent améliorant l'arthrose. L'invention concerne un agent améliorant l'arthrose qui comprend un dérivé de trans-astaxanthine représenté par la formule (I), un isomère géométrique de celui-ci, un mélange d'isomères géométriques de celui-ci, un isomère optique de celui-ci ou un sel de celui-ci [dans la formule (I), m1, m2, n1 et n2 sont identiques ou différents et représentent un entier de 1 à 6].
PCT/JP2018/035563 2017-09-27 2018-09-26 Agent améliorant l'arthrose WO2019065674A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017185873A JP2021008404A (ja) 2017-09-27 2017-09-27 変形性関節症改善剤
JP2017-185873 2017-09-27

Publications (1)

Publication Number Publication Date
WO2019065674A1 true WO2019065674A1 (fr) 2019-04-04

Family

ID=65901442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/035563 WO2019065674A1 (fr) 2017-09-27 2018-09-26 Agent améliorant l'arthrose

Country Status (2)

Country Link
JP (1) JP2021008404A (fr)
WO (1) WO2019065674A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114026095A (zh) * 2019-06-06 2022-02-08 豪夫迈·罗氏有限公司 用于制备4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氢嘧啶-6-基]甲基]-3-氧代-5,6,8,8a-四氢-1H-咪唑并[1,5-a]吡嗪-2-基]-甲酸的替代方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015178404A1 (fr) * 2014-05-20 2015-11-26 富士化学工業株式会社 Dérivé de caroténoïde, sel pharmaceutiquement acceptable de ce dernier et ester ou amide pharmaceutiquement acceptable de ce dernier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015178404A1 (fr) * 2014-05-20 2015-11-26 富士化学工業株式会社 Dérivé de caroténoïde, sel pharmaceutiquement acceptable de ce dernier et ester ou amide pharmaceutiquement acceptable de ce dernier

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN, W P ET AL.: "Astaxanthin reduces matrix metalloproteinase expression in human chondrocytes", INT IMMUNOPHARMACOL, vol. 19, no. 1, 2014, pages 174 - 177, XP028618156, DOI: doi:10.1016/j.intimp.2013.12.007 *
HUANG, L J ET AL.: "Astaxanthin ameliorates cartilage damage in experimental osteoarthritis", MOD RHEUMATO, vol. 25, no. 5, 2015, pages 768 - 771 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114026095A (zh) * 2019-06-06 2022-02-08 豪夫迈·罗氏有限公司 用于制备4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氢嘧啶-6-基]甲基]-3-氧代-5,6,8,8a-四氢-1H-咪唑并[1,5-a]吡嗪-2-基]-甲酸的替代方法

Also Published As

Publication number Publication date
JP2021008404A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
JP3231043B2 (ja) 薬理活性を有する硝酸エステルおよびその製法
KR101493125B1 (ko) 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
AU2011344030B2 (en) 3-methanesulfonylpropionitrile for treating inflammation and pain
US20090062372A1 (en) Glycopyrronium Salts and Their Therapeutic Use
JPH0137398B2 (fr)
US11066423B2 (en) Monomeric bimetal hydroxycitric acid compounds and methods of making and using the same
US20090036516A1 (en) Compounds for treating metabolic syndrome
ES2856204T3 (es) Compuestos de ciclohexenilo, composiciones que los comprenden y usos de los mismos
WO2008080955A1 (fr) Dérivés de mononitrate d'isosorbide pour le traitement de troubles intestinaux
WO2019065674A1 (fr) Agent améliorant l'arthrose
KR100979077B1 (ko) 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물
JP6173352B2 (ja) 筋萎縮性側索硬化症の治療方法
TW201309288A (zh) 鎮痛劑
WO2019111897A1 (fr) Remède contre la dermatite
US11292759B2 (en) Hydroxycitric acid metal heterocyclic compounds with covalent characteristics
CN114349665B (zh) 二甲双胍焦谷氨酸晶体及其制备方法与应用
WO2019111896A1 (fr) Agent antiprurigineux
JPH09505813A (ja) ビフェニル沃素化誘導体及びその診断用途
JP2019099505A (ja) 脳血管障害治療剤
CN105949277B (zh) 一种抗肿瘤化合物及其用途
CA3230557A1 (fr) Compose antagoniste ep4, sel, polymorphe et utilisation associee
CN115703727A (zh) 一种过硫化氢前药及其制药用途
JP2019043884A (ja) 敗血症治療剤
JPH03193758A (ja) 新規γ―アミノ酪酸誘導体
CN111727039A (zh) 大肠炎改善剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18863075

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18863075

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP